ReviewCells2026
Targeting Gut Microbiota, Inflammation, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: Therapeutic Strategies and the Emerging Role of Time-Restricted Feeding.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Time-restricted feeding has emerged as a promising non-pharmacological intervention for the management of metabolic disorders, particularly type 2 diabetes mellitus and its associated complications. Time-restricted feeding involves restricting food intake to a specific daily eating window while fasting for the remaining hours within 24 h. Furthermore, time-restricted feeding can be combined with specific dietary modifications to enhance its therapeutic benefits. Type 2 diabetes mellitus has been strongly linked to gut dysbiosis, adipose tissue dysfunction, chronic low-grade inflammation, metabolic dysfunction-associated steatotic liver disease, and an increased risk of acute pancreatitis. Given the rising global prevalence of type 2 diabetes mellitus, early intervention strategies are becoming increasingly important. Prediabetes, as an intermediate stage preceding type 2 diabetes mellitus, provides a critical opportunity to understand the mechanisms underlying disease progression and to develop effective preventive strategies. However, the effects of time-restricted feeding on gut dysbiosis, adipose tissue dysfunction, dysregulated inflammatory responses, metabolic dysfunction-associated steatotic liver disease and the risk of acute pancreatitis at prediabetic state remain incompletely understood. Therefore, this review summarizes the current evidence regarding the therapeutic potential of time-restricted feeding in the management of type 2 diabetes mellitus and its related complications, while highlighting areas that require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.